High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

M. Terwijn, W.L.J. van Putten, A. Kelder, V.H.J. van der Velden, R.A. Brooimans, T. Pabst, J. Maertens, N. Boeckx, G.E. de Greef, P.J.M. Valk, F.W.M.B. Preijers, P.C. Huijgens, A.M. Drager, U. Schanz, M. Jongen-Lavrecic, B.J. Biemond, J.R. Passweg, M. van Gelder, P. Wijermans, C. GrauxM. Bargetzi, M.C. Legdeur, J. Kuball, O. de Weerdt, Y. Chalandon, U. Hess, L.F. Verdonck, J.W. Gratama, Y.J.M. Oussoren, W.J. Scholten, J. Slomp, A.N. Snel, M.C. Vekemans, B. Lowenberg, G.J. Ossenkoppele, G.J. Schuurhuis

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)3889-3897
JournalJournal of Clinical Oncology
Volume31
Issue number31
DOIs
Publication statusPublished - 2013

Cite this